This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
While immunotherapy has been remarkably effective against several types of advanced cancer, these benefits have so far failed to materialize for patients with advanced breast cancer. In order to improve outcomes for these patients, Dr. Li Wang is exploring the therapeutic potential of a new cancer immunotherapy target that she recently discovered on T cells that also appears to be a prognostic marker for breast cancer. Specifically, Dr. Wang is using mouse models of breast cancer to establish how this novel receptor regulates cancer-targeting T cell responses, and then aims to develop and test an antibody that targets this receptor. The insights gained would then provide a foundation for the future development of therapeutic agents against this new T cell target in breast cancer patients.
Medical College of Wisconsin | Breast Cancer | 2018
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).
Drs. Stefani Spranger and Elsa Anagnostou recap highlights relating to myeloid cells, tumor heterogeneity, and preclinical models from Day 2 of of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).